| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 03/27/2002 | EP1189881A1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| 03/27/2002 | EP1189662A1 Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist |
| 03/27/2002 | EP1189638A2 Pharmaceutical composition containing sibutramine and a lipase inhibitor |
| 03/27/2002 | EP1189629A2 Methods and reagents for treating glucose metabolic disorders |
| 03/27/2002 | EP1189621A1 Unfermented gel fraction from psyllium seed husks |
| 03/27/2002 | EP1189616A2 S-hydroxynefazodone |
| 03/27/2002 | EP1189612A1 Vla-4 inhibitor compounds |
| 03/27/2002 | EP1189609A1 Cxcr-4 receptor antagonists - thrombopoietin mimetics |
| 03/27/2002 | EP1189605A2 High molecular weight primary aliphatic alcohols obtained from beeswax and pharmaceutical use thereof |
| 03/27/2002 | EP1189598A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 03/27/2002 | EP1189593A1 Cosmetic compositions containing pantothenic acid |
| 03/27/2002 | EP1189583A1 Indole derivatives |
| 03/27/2002 | EP1189522A1 Use of nanoscale sterols and sterol esters |
| 03/27/2002 | EP0946562B1 PYRROLO[3,4-d]PYRIMIDINONE DERIVATIVES AND THEIR USE AS IMMUNOSUPPRESSANTS |
| 03/27/2002 | EP0946503B1 Nitromethylthiobenzene derivatives as inhibitors of aldose reductase |
| 03/27/2002 | EP0865421B1 Arylethanolamine derivatives and their use as agonists of atypical beta-adrenoceptors |
| 03/27/2002 | EP0831906B1 Treatment of t cell mediated autoimmune disorders |
| 03/27/2002 | EP0790996B1 Pyridazinoquinoline compounds |
| 03/27/2002 | CN1342206A Adenoviruses deleted in IVa2, 100K and/or preterminal protein sequences |
| 03/27/2002 | CN1342202A Soluble receptor BR43X2 and methods for using them for therapy |
| 03/27/2002 | CN1342193A Method for obtaining oil that rich in hydroxyoctadecadienoic fatty acids (hode) or esters thereof from mixture containing linoleic acid or esters thereof |
| 03/27/2002 | CN1342169A Oxetanone derivatives |
| 03/27/2002 | CN1342167A Low molecular weight peptide derivatives as inhibitors of laminin/nidogen interaction |
| 03/27/2002 | CN1342166A GLP-1 analogues |
| 03/27/2002 | CN1342162A Substituted 2-acyl-3-(heteroaryl)-imidazo [1,2-a] pyrimidines, and related pharmaceutical compoistions and methods |
| 03/27/2002 | CN1342161A Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| 03/27/2002 | CN1342153A Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in production of medicaments |
| 03/27/2002 | CN1342091A Combinations of cardiovascular indications |
| 03/27/2002 | CN1342090A Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular disease |
| 03/27/2002 | CN1342089A Combinations of ileal bile acid transport inhibitors and cholestery ester transfer protein inhibitors for cardiovascular disease |
| 03/27/2002 | CN1342083A Uses of 1-amino-3-(N,N-dimethylamino)propylidene-1,1-bisphosphonic acid |
| 03/27/2002 | CN1342082A Use of tianeptin in production of medicaments to treat neurodegenerative pathologies |
| 03/27/2002 | CN1342077A Inhibition of formation of vascular hyperpermeability |
| 03/27/2002 | CN1342072A Method for preventing or delaying catheter-based revascularization |
| 03/27/2002 | CN1342068A Core tablet for controlled release of gliclazide after oral administration |
| 03/27/2002 | CN1341588A Intermediate product for preparing substituted 2,4-thiazolidine diketone derivative |
| 03/27/2002 | CN1341447A Fat-reducing weight-reducing chewing gum and its production method |
| 03/27/2002 | CN1341444A Health-care product with function of regulating blood sugar and its preparation method |
| 03/27/2002 | CN1341442A Taxus chinensis health-care composite for reducing blood sugar |
| 03/27/2002 | CN1341426A Scorpion growth-promoting agent |
| 03/27/2002 | CN1341421A Shaliwikang soft capsule |
| 03/27/2002 | CN1081632C Form III crystalline (R-(R*,R*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
| 03/27/2002 | CN1081460C Use of medicine for reducing tissue damage associated with non-cardiac ischemia by aldose reductase inhibitor |
| 03/26/2002 | US6362360 Sensitizers for insulin resistance and associated conditions dyslipidemia and hyperglycemia |
| 03/26/2002 | US6362324 Used as target for diagnosis and treatment in aminopeptidase-related disorders such as aging, cancers, cataracts, cystic fibrosis and leukemias; used in drug-screening to identify agonists, antagonists |
| 03/26/2002 | US6362322 Conversion of a watson-crick DNA to a hoogsteen-paired duplex |
| 03/26/2002 | US6362236 Statin compound |
| 03/26/2002 | US6362220 Administering a sulfamic acid compound |
| 03/26/2002 | US6362211 Polycyclic indanylimidazoles with alpha2 adrenergic activity |
| 03/26/2002 | US6362198 Anticholesterol, antilipemic agent |
| 03/26/2002 | US6362195 Inhibitor of nitric oxide synthase; central nervous system disorders |
| 03/26/2002 | US6362185 Polyhydroxyalkylpyrazine derivatives, their preparation and the medicaments comprising them |
| 03/26/2002 | US6362182 Hypotensive agents; anticholesterol agents; benign prostatic hypertropic |
| 03/26/2002 | US6362163 Administering polypeptide |
| 03/26/2002 | US6361795 Method for lowering blood glucose |
| 03/26/2002 | US6361771 Implantable cell culture device comprising semipermeable membrane permitting diffusion of growth factor therethrough, and arpe-19 cells genetically engineered to produce growth factor disposed within semipermeable membrane |
| 03/26/2002 | US6361768 Hydrophilic ampholytic polymer |
| 03/26/2002 | US6361758 Cosolvent formulations |
| 03/26/2002 | US6360651 Home-style decoctor endowed with steamy boiling function, and method of preparing red ginseng extract using the same |
| 03/26/2002 | CA2234249C Therapeutic diet for dogs with lymphoma |
| 03/26/2002 | CA2089954C 4-amino-2-ureidopyrimidine-5-carboxamides, a process for the preparation thereof, pharmaceuticals containing these compounds, and the use thereof |
| 03/26/2002 | CA2072513C Lozenge or chewable tablet |
| 03/26/2002 | CA2054409C Fat mixture for infant and adult nutrition |
| 03/21/2002 | WO2002023184A1 Method for treatment of insulin resistance in obesity and diabetes |
| 03/21/2002 | WO2002022818A1 Human and rat pgc-3, ppar-gamma coactivations and splice variants thereof |
| 03/21/2002 | WO2002022805A2 Modulation of il-2- and il-15-mediated t cell responses |
| 03/21/2002 | WO2002022684A2 Transporters and ion channels |
| 03/21/2002 | WO2002022682A1 Interferon-alpha induced gene |
| 03/21/2002 | WO2002022680A2 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine) |
| 03/21/2002 | WO2002022677A2 Variants of allergenic proteins of the group 2 of dermatophagoides |
| 03/21/2002 | WO2002022635A1 Antisense modulation of clusterin expression |
| 03/21/2002 | WO2002022630A1 Purine derivatives |
| 03/21/2002 | WO2002022611A2 Caspase inhibitors and uses thereof |
| 03/21/2002 | WO2002022610A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | WO2002022608A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022607A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022606A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022605A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022604A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022603A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022602A2 Triazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022601A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022599A2 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | WO2002022592A2 Substituted urea neuropeptide y y5 receptor antagonists |
| 03/21/2002 | WO2002022572A2 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | WO2002022562A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022561A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022558A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022212A2 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | WO2002022170A1 Insulin secretion controlling agents |
| 03/21/2002 | WO2002022166A2 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | WO2002022161A2 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | WO2002022160A2 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | WO2002022151A2 Use of glp-1 and flp-2 peptides for treatment of bone disorders |
| 03/21/2002 | WO2002022146A2 Components of canola for treating hyperlipidemia |
| 03/21/2002 | WO2002022140A1 Homeostasis-maintaining agents |
| 03/21/2002 | WO2002022135A1 Creatine ester pronutrient compounds and formulations |
| 03/21/2002 | WO2002022134A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 03/21/2002 | WO2002022123A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | WO2002022122A1 Use of compounds for the treatment of obesity |